Pinnacle Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pinnacle Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,115	Closed	-$345K	–	972
2026 Q1	$345K	Sell	6,115 -6	-0.1%	-$350	﹤0.01%	754
2025 Q4	$364K	Buy	+6,121	New	+$333K	﹤0.01%	731
2022 Q2	–	Sell	-5,612	Closed	-$433K	–	753
2022 Q1	$433K	Buy	+5,612	New	+$470K	0.01%	590

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pinnacle Associates's BMRN Position: Q2 2026 in Review

Pinnacle Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 6,115 shares — an estimated $345K sold.

Pinnacle Associates first reported a position in BMRN in Q1 2022 and held it in 3 quarters. The position peaked at $433K in Q1 2022. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Pinnacle Associates reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Pinnacle Associates sold 6,115 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $345K.
Pinnacle Associates first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Pinnacle Associates's BioMarin Pharmaceuticals position peaked at $433K in Q1 2022.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.